BRISBANE, Calif. — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on advanced solutions for transplant patients and caregivers, announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025.
Dr. Teuteberg brings more than 20 years of experience in clinical transplantation and leadership at top academic institutions, including Stanford University and the University of Pittsburgh Medical Center. Board certified in Heart Failure/Cardiac Transplantation and Cardiovascular Medicine, he has served as Section Chief of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support at Stanford since 2017.
Internationally recognized for his leadership in the field, Dr. Teuteberg has held prominent roles in the American Society of Transplantation (AST) and the International Society for Heart and Lung Transplantation (ISHLT), including serving as ISHLT President and chairing multiple committees and task forces. He was also the principal investigator for the Surveillance HeartCare Outcomes Registry (SHORE) study, which advanced understanding of noninvasive rejection surveillance and outcomes in heart transplantation. His work on multicenter clinical trials and guideline committees has helped shape heart transplant care worldwide.
“I am honored to join CareDx at such a pivotal time for the field of transplantation,” said Dr. Teuteberg. “Through my research, particularly as principal investigator of the SHORE study, I have witnessed the transformative impact of data-driven innovation on the patient experience and their outcomes. I look forward to helping CareDx drive the next generation of innovative solutions for transplant patients and the clinicians who care for them.”
“Dr. Teuteberg’s deep clinical expertise and leadership in transplant medicine are a tremendous fit for CareDx,” said John Hanna, President and Chief Executive Officer of CareDx. “His commitment to advancing patient care and his track record of clinical innovation will be invaluable as we continue to deliver on our mission to create life-changing solutions that enable transplant patients to thrive.”
In his new role, Dr. Teuteberg will lead CareDx’s global Medical Affairs organization, overseeing Medical Directors, Medical Science Liaisons, and clinical research operations as the company continues to expand its leadership in transplantation science and patient-centered innovation.
